TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06548672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC3195
Description: BC3195 is a novel antibody drug conjugate (ADC) targeting CDH3 (calcium-dependent adhesion 3). The payload, monomethyl auristatin E (MMAE), is a microtubule disrupting agent covalently attached to the antibody via a cleavable dipeptide linker Val-Cit (vc).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC3195
Description: BC3195 is a novel antibody drug conjugate (ADC) targeting CDH3 (calcium-dependent adhesion 3). The payload, monomethyl auristatin E (MMAE), is a microtubule disrupting agent covalently attached to the antibody via a cleavable dipeptide linker Val-Cit (vc).
Study: NCT04736810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK105
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Oral administration
Study: NCT04846153

Intervention type: OTHER
Group type: OTHER
Intervention: Human-based Quantification of Airway Stenosis
Description: Human-based Quantification of Airway Stenosis From Bronchoscopic Images.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.
Description: Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.
Study: NCT05182203

Intervention type: DRUG
Intervention: biologic/targeted therapy
Description: TNF inhibitors or the JAK inhibitors

Intervention type: DRUG
Intervention: biologic/targeted therapy
Description: TNF inhibitors or the JAK inhibitors
Study: NCT04709276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360 mg intravenously every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg intravenously every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 4 mg/ml per minute intravenously every 3 weeks for up to 10 cycles.~Subjects will also receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 20 or 25 mg/m2 intravenously every 3 weeks for up to 10 cycles.~Subjects will also take prednisone by mouth at a dose of 10 mg daily and receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving cabazitaxel.
Study: NCT04889495

Intervention type: DRUG
Intervention: Zirabev
Description: Bevacizumab biosimilar
Study: NCT06172257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone ophthalmic suspension (OCS-01)
Description: The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: The vehicle drug (placebo) eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Subjects will be dosed with eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
Study: NCT05588804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broncho-munal®
Description: 1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
Study: NCT04663867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioSafe Peripheral CTO Crossing System
Description: The AngioSafe Peripheral CTO Crossing System is intended to facilitate the intraluminal placement of guidewires beyond stenotic lesions, including chronic total occlusions (CTOs) in the peripheral vasculature.
Study: NCT05807828

Intervention type: PROCEDURE
Group type: OTHER
Intervention: VR simulation on basic THA skills
Description: The medical students' VR group will perform three VR simulation sessions on basic THA skills on the cup and stem implantation before actual implantation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: VR simulation on basic THA skills
Description: The medical students' VR group will perform three VR simulation sessions on basic THA skills on the cup and stem implantation before actual implantation.
Study: NCT06065956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Description: Morphine group(an opioid), participants were given intravenous morphine(an opioid) at induction of General Anaesthesia before laryngoscopy and intubation.~The other group,Esmolol group(cardioselective beta blocker), participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Description: Morphine group(an opioid), participants were given intravenous morphine(an opioid) at induction of General Anaesthesia before laryngoscopy and intubation.~The other group,Esmolol group(cardioselective beta blocker), participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation.
Study: NCT05720078

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive, two-phase RT
Description: Participants in this arm will be treated with an adaptive, two-phase radiation therapy approach
Study: NCT05035186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Anti-H. pylori regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Anti-H. pylori regimens
Study: NCT06428474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: Oral health education program designed for orphans children
Study: NCT05390320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PAOO
Description: Periodontally accelerated osteogenic orthodontics will be applied to treat patients with moderate crowding.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed appliance
Description: Fixed appliances will be applied to treat patients with moderate crowding without any acceleration methods.
Study: NCT05708599

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Description: Liquid biopsy
Study: NCT05107778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 0.5 mg orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 0.5 mg orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: Entecavir 0.5 mg orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally once daily.
Study: NCT05700799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Advocate
Description: The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
Study: NCT06524804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BY101298 Capsules
Description: An oral DNA-PK Inhibitor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: palliative radiotherapy
Description: Undergo palliative radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BY101298 Capsules
Description: An oral DNA-PK Inhibitor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: curative radiotherapy
Description: Undergo curative radiotherapy
Study: NCT05941052

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tongue swab-based molecular assays
Description: The investigators will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
Study: NCT05561088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scalp Acupuncture
Description: mplementation plan of head needle: The middle frontal line (MS1), the middle parietal line (MS5) and the back parietal and temporal oblique line (MS7) in the International Standardization Program for the Name of the first needle Point in 1989 were selected, and the needles were inserted along the shape of each section. One needle was inserted into the middle frontal line and the middle parietal line, and two needles were inserted into the back parietal and temporal oblique line. The KWD-808I pulse electrotherapy instrument produced by Changzhou Wujin Great Wall Medical Equipment Co., Ltd. is used on the needle handle after lifting, inserting and twisting. The continuous waveform was used, the voltage was 2-4 V, the frequency was 60-80 times /min, the intensity was tolerated by the patient, the needle was kept for 30min, and the treatment was performed once a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The treatment recommended in the guidelines for acute ischemic stroke was administered
Description: The treatment recommended in the guidelines for acute ischemic stroke was administered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The treatment recommended in the guidelines for acute ischemic stroke was administered
Description: The treatment recommended in the guidelines for acute ischemic stroke was administered
Study: NCT04750590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: en bloc resection, morcellation
Description: Laser en bloc resection with subsequent tumor morcellation will be performed. This tissue will be sent for histology in order to estimate the histological subtype and differentiation grade. Next stage laser resection of the tumor basis will be performed with subsequent histology to determine the depth of invasion and the status of surgical margin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piecemeal resection, tissue removal by loop
Description: Tumor piecemeal resection will be performed with electric loop. Then fragments of the tumor will be removed by the loop or Janet's syringe. Fragments from the base of the tumor will be sent separately in order to assess which stage the tumor is at and its surgical margin status.
Study: NCT06385470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Temporal and Tactile Cueing treatment
Description: DTTC is a motor-based treatment designed for children with CAS who may have limited verbal output. It applies the principles of motor learning and focuses on speech movement gestures in the context of functional words and phrases.~The participants will receive two versions of the DTTC treatment (i.e., DTTC in English \[DTTC-E\] and DTTC in Cantonese \[DTTC-C\]), where probe data will be collected before, during, between and after the treatment intervention.
Study: NCT05929456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800
Description: patients will receive a single IV injection of Cetuximab-IRDye800CW 2-4 days prior to surgert. The IMP (Investigational medicinal product)/tracer will be used for fluorescence guided surgery.
Study: NCT06661031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy plus Ecological Momentary Intervention
Description: Two Motivational Enhancement Therapy (MET) sessions (1st, \~45 minutes; 2nd, \~30 minutes) between counselor and participant occur one week apart. MET sessions are personalized, interactive, face-to-face, and delivered according to a manual. MET session discussion topics include triggers for cannabis use, life goals/values, and development of a change plan. Participants then complete a 2-week Ecological Momentary Intervention (EMI) period. Survey prompts are sent 4x/day (3x/day at quasi-randomized times, 1x/day at fixed time; \~2 mins each) that ask about the participant's recent cannabis use. Depending on answers reported, the participant can receive tailored messages that support their self-efficacy and prompt use of coping strategies.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Usual Care
Description: Participants meet with a study counselor 1-on-1 via videoconference to review a brochure containing cannabis information and treatment resources.
Study: NCT06613555

Intervention type: OTHER
Intervention: Retinal imaging
Description: the retinal imaging work-up includes:~* OCT-angiography~* Retinophotography~* Adaptive optics~performed at inclusion, at 6 months and then once a year for 10 years for patients Only performed at inclusion for controls

Intervention type: OTHER
Intervention: Retinal imaging
Description: the retinal imaging work-up includes:~* OCT-angiography~* Retinophotography~* Adaptive optics~performed at inclusion, at 6 months and then once a year for 10 years for patients Only performed at inclusion for controls

Intervention type: BIOLOGICAL
Intervention: Biological check-up
Description: it is performed at inclusion and then once a year for 10 years for patients~Only performed at inclusion for controls

Intervention type: BIOLOGICAL
Intervention: Biological check-up
Description: it is performed at inclusion and then once a year for 10 years for patients~Only performed at inclusion for controls
Study: NCT04832412

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BrainPhyt
Description: BrainPhyt low dose supplementation during 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 100 % Maltodextrin
Description: 100 % Maltodextrin
Study: NCT06696898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Somatosensory Motor Control Exercises
Description: The Somatosensory motor control training protocol assembled into three components, 1) PNF exercises (Each patient alternately contracted trunk extensors and flexors isometrically for 10 seconds against maximum resistance while seated, then contracted trunk agonists alternately in a concentric and eccentric manner against manual resistance without relaxing, then moved his or her trunk in a twisting and diagonal orientation against maximum resistance), 2) Somatosensory exercises in which a wobbling board was used and six types of exercises were performed including hallowing, one lower limb elevation, opposite upper and lower limb elevation from a four-limb supported position (quadruped), abdominal reinforcement, maintaining a bridging posture, and one lower limb elevation from the bridging posture, and 3) finally Vestibular training which involved exercises to improve gaze focus, exercises for enhancing eye movements.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial Release Technique
Description: Manual therapy technique that applies sustained pressure to myofascial tissues around the lumbar spine and pelvis to release tension and improve mobility.Myofascial Release Technique MFR is given with the ulnar border from proximal to distal direction with a light gentle pressure over the hamstring muscle until the slack in the skin is loosened. (2) Every strike is to be held for 30 seconds, 5 repetitions per session

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sensorymotor training
Description: The Somatosensory motor control training protocol assembled into three components, 1) PNF exercises (Each patient alternately contracted trunk extensors and flexors isometrically for 10 seconds against maximum resistance while seated, then contracted trunk agonists alternately in a concentric and eccentric manner against manual resistance without relaxing, then moved his or her trunk in a twisting and diagonal orientation against maximum resistance), 2) Somatosensory exercises in which a wobbling board was used and six types of exercises were performed including hallowing, one lower limb elevation, opposite upper and lower limb elevation from a four-limb supported position (quadruped), abdominal reinforcement, maintaining a bridging posture, and one lower limb elevation from the bridging posture, and 3) finally Vestibular training which involved exercises to improve gaze focus, exercises for enhancing eye movements.
Study: NCT06706739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online art game intervention group
Description: The researchers conducted a prospective randomized controlled trial in which elderly patients with mild cognitive impairment combined with subthreshold depression who met the inclusion exclusion criteria were randomized into an online art game intervention group and a health education control group, with each group receiving an individualized intervention for 12 weeks. Participants in the experimental group created comic strips through an art game platform developed by the researchers' research team.
Study: NCT06728280

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep transcranial magnetic stimulation with H1coil
Description: Participants will receive dTMS treatment with H1 coil

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep transcranial magnetic stimulation with H7 coil
Description: Participants will receive dTMS treatment with H7 coil
Study: NCT06723392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral nitrofurantoin monohydrate/macrocrystals
Description: 7-day course of oral nitrofurantoin monohydrate/macrocrystals 100 mg twice daily (total of 14 doses)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7-day course of oral placebo 100 mg twice daily (total of 14 doses)
Study: NCT06731699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FD-001
Description: The initial dose was 0.4mg, and subsequent doses of 0.8mg, 1.6mg, 2.4mg, 3.2mg, and 4.0mg were proposed to be administered in a progressive manner using the rapid titration method combined with the traditional 3+3 experimental design. The trial process consists of three periods: screening period, treatment period, and follow-up period. The screening period lasted from D-28 to D-1 for treatment (DLT observation period): during this time frame, there was a single administration period (C0D1-C0D4) where oral administration occurred on day one followed by safety observations on days two to four; as well as multiple administration period one (C1D1-C1D28) where oral administration took place on days one to two and seven to nine with rest periods in between. The drug is available in capsule form.
Study: NCT06739343

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PHACO-Trabeculectomy
Description: Phaco-Trabeculectomy is a combined surgical procedure that integrates phacoemulsification, a modern cataract extraction technique using ultrasound, with trabeculectomy, a glaucoma filtration surgery. This intervention is distinguished by its precision, minimal incision size, and suitability for patients with coexisting cataract and glaucoma. Phacoemulsification efficiently emulsifies and aspirates the cataract through a small incision, while trabeculectomy creates a filtration bleb to lower intraocular pressure (IOP). This combination allows for simultaneous management of both conditions, particularly in cases where phacoemulsification is preferred for cataract extraction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PHACO-Trabeculectomy
Description: Phaco-Trabeculectomy is a combined surgical procedure that integrates phacoemulsification, a modern cataract extraction technique using ultrasound, with trabeculectomy, a glaucoma filtration surgery. This intervention is distinguished by its precision, minimal incision size, and suitability for patients with coexisting cataract and glaucoma. Phacoemulsification efficiently emulsifies and aspirates the cataract through a small incision, while trabeculectomy creates a filtration bleb to lower intraocular pressure (IOP). This combination allows for simultaneous management of both conditions, particularly in cases where phacoemulsification is preferred for cataract extraction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MSICS-Trabeculectomy
Description: Manual Small Incision Cataract Surgery (MSICS) with Trabeculectomy is a cost-effective, combined surgical approach involving a manual technique for cataract removal alongside glaucoma filtration surgery. MSICS utilizes a larger incision than phacoemulsification, allowing for the manual extraction of the cataract nucleus. This procedure is particularly advantageous in resource-limited settings where phacoemulsification equipment may not be available. The trabeculectomy component is the same as in the PHACO-Trabeculectomy intervention, providing effective IOP reduction through the creation of a filtration bleb.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MSICS-Trabeculectomy
Description: Manual Small Incision Cataract Surgery (MSICS) with Trabeculectomy is a cost-effective, combined surgical approach involving a manual technique for cataract removal alongside glaucoma filtration surgery. MSICS utilizes a larger incision than phacoemulsification, allowing for the manual extraction of the cataract nucleus. This procedure is particularly advantageous in resource-limited settings where phacoemulsification equipment may not be available. The trabeculectomy component is the same as in the PHACO-Trabeculectomy intervention, providing effective IOP reduction through the creation of a filtration bleb.
Study: NCT05381636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal arterial infusion chemotherapy
Description: Percutaneous femoral artery puncture was performed to search for feeding arterial vessels corresponding to the lesion, and chemotherapeutic drugs were directly injected into the tumor vessels via targeted blood vessels.
Study: NCT06739304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Relapse Prevention
Description: 250 adult USD females of Intervention group received the 8-week Group mindfulness intervention performed by psychiatrists.
Study: NCT06739967

Intervention type: BEHAVIORAL
Intervention: Behavioral Treatment
Description: The SLT intervention will be entirely administered online through a web-based platform. While each of the treatments will engage semantics, phonology, and orthography, the protocols will be tailored relative to the characteristics of each PPA variant. Patients with svPPA and lvPPA will undergo a lexical retrieval training (LRT) intervention implemented using a training cascade.~Patients with nfvPPA will undergo Video-implemented Script Training (VISTA), a choral reading approach training accurate production of functional scripts. The method is based on that implemented in American-English individuals with PPA and aims at improving grammar and motor aspects of speech production by taking advantage of repetitive practice and automaticity.